Last updated on November 2018

Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Brief description of study

This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).

Clinical Study Identifier: NCT02908100

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GA30044 ...

Chang Gung Memorial Hospital - Linkou
Taoyuan, Taiwan